Diego Carrera

TL;DR: It is concluded that blood-derived TAMs significantly infiltrate pre-treatment gliomas, to a degree that varies by glioma subtype and tumor compartment, and a novel signature that distinguishes TAMs by ontogeny in humangliomas is presented.

TL;DR: The findings demonstrate a mechanism of immune evasion in IDH-MUT gliomas and suggest that specific inhibitors of mutant IDH may improve the efficacy of immunotherapy in patients with IDH -MUTgliomas.

TL;DR: Adoptive transfer of TCR-transduced T cells significantly suppressed the progression of glioma xenografts in mice and provided a strong basis for developing T cell–based therapy targeting this shared neoepitope.

TL;DR: In this article, a synNotch receptor that recognizes a specific priming antigen, such as the heterogeneous but tumor-specific glioblastoma neoantigen epidermal growth factor receptor splice variant III (EGFRvIII) or the central nervous system (CNS) tissue-specific antigen myelin oligodendrocyte glycoprotein (MOG), was used to locally induce expression of a CAR.

TL;DR: Targeting GLUT3 or the increased glycolysis reliance in resistant tumors could unlock the potential of antiangiogenic treatments.